Tags

Type your tag names separated by a space and hit enter

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
J Clin Endocrinol Metab. 2015 Feb; 100(2):697-706.JC

Abstract

CONTEXT

Abaloparatide is a novel synthetic peptide analog of parathyroid hormone-related protein (PTHrP) that is currently being developed as a potential anabolic agent in the treatment of postmenopausal osteoporosis.

OBJECTIVE

This study sought to assess the effects of abaloparatide on bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck in postmenopausal women with osteoporosis.

DESIGN

Multi-center, multi-national, double-blind placebo controlled trial in which postmenopausal women were randomly assigned to receive 24 weeks of treatment with daily sc injections of placebo, abaloparatide, 20, 40, or 80 μg, or teriparatide, 20 μg. A 24-week extension was also performed in a subset of subjects.

PARTICIPANTS

Postmenopausal women with osteoporosis (n = 222).

MAIN OUTCOME MEASURES

BMD by dual-x-ray absorptiometry and biochemical markers of bone turnover.

RESULTS

At 24 weeks, lumbar spine BMD increased by 2.9, 5.2, and 6.7% in the abaloparatide, 20-, 40-, and 80-μg groups, respectively, and 5.5% in the teriparatide group. The increases in the 40- and 80-μg abaloparatide groups and the teriparatide group were significantly greater than placebo (1.6%). Femoral neck BMD increased by 2.7, 2.2, and 3.1% in abaloparatide, 20-, 40-, and 80-μg groups, respectively, and 1.1% in the teriparatide group. The increase in femoral neck BMD with abaloparatide, 80 μg was significantly greater than placebo (0.8%). Total hip BMD increased by 1.4, 2.0, and 2.6% in the abaloparatide, 20-, 40-, and 80-μg groups, respectively. The total hip increases in the 40- and 80-μg abaloparatide groups were greater than both placebo (0.4%) and teriparatide (0.5%).

CONCLUSIONS

Compared with placebo, 24 weeks of daily sc abaloparatide increases BMD of the lumbar spine, femoral neck, and total hip in a dose-dependent fashion. Moreover, the abaloparatide-induced BMD increases at the total hip are greater than with the marketed dose of teriparatide. These results support the further investigation of abaloparatide as an anabolic therapy in postmenopausal osteoporosis.

Authors+Show Affiliations

Endocrine Unit, Department of Medicine (B.Z.L.), Massachusetts General Hospital,, Harvard Medical School, Boston, Massachusetts 02114; Radius Health Inc. (L.S.O., K.B., K.M., C.R.L., G.H.), Waltham, Massachusetts 02451; Centre for Diabetes & Endocrine Care (P.K.), Karnataka 560043, India; and Instituto de Diagnóstico e Investigaciones Metabólicas (J.R.Z.), Buenos Aires, Argentina.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25393645

Citation

Leder, Benjamin Z., et al. "Effects of Abaloparatide, a Human Parathyroid Hormone-related Peptide Analog, On Bone Mineral Density in Postmenopausal Women With Osteoporosis." The Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 2, 2015, pp. 697-706.
Leder BZ, O'Dea LS, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015;100(2):697-706.
Leder, B. Z., O'Dea, L. S., Zanchetta, J. R., Kumar, P., Banks, K., McKay, K., Lyttle, C. R., & Hattersley, G. (2015). Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. The Journal of Clinical Endocrinology and Metabolism, 100(2), 697-706. https://doi.org/10.1210/jc.2014-3718
Leder BZ, et al. Effects of Abaloparatide, a Human Parathyroid Hormone-related Peptide Analog, On Bone Mineral Density in Postmenopausal Women With Osteoporosis. J Clin Endocrinol Metab. 2015;100(2):697-706. PubMed PMID: 25393645.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. AU - Leder,Benjamin Z, AU - O'Dea,Louis St L, AU - Zanchetta,José R, AU - Kumar,Prasana, AU - Banks,Kathleen, AU - McKay,Kathleen, AU - Lyttle,C Richard, AU - Hattersley,Gary, Y1 - 2014/11/13/ PY - 2014/11/14/entrez PY - 2014/11/14/pubmed PY - 2015/4/15/medline SP - 697 EP - 706 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 100 IS - 2 N2 - CONTEXT: Abaloparatide is a novel synthetic peptide analog of parathyroid hormone-related protein (PTHrP) that is currently being developed as a potential anabolic agent in the treatment of postmenopausal osteoporosis. OBJECTIVE: This study sought to assess the effects of abaloparatide on bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck in postmenopausal women with osteoporosis. DESIGN: Multi-center, multi-national, double-blind placebo controlled trial in which postmenopausal women were randomly assigned to receive 24 weeks of treatment with daily sc injections of placebo, abaloparatide, 20, 40, or 80 μg, or teriparatide, 20 μg. A 24-week extension was also performed in a subset of subjects. PARTICIPANTS: Postmenopausal women with osteoporosis (n = 222). MAIN OUTCOME MEASURES: BMD by dual-x-ray absorptiometry and biochemical markers of bone turnover. RESULTS: At 24 weeks, lumbar spine BMD increased by 2.9, 5.2, and 6.7% in the abaloparatide, 20-, 40-, and 80-μg groups, respectively, and 5.5% in the teriparatide group. The increases in the 40- and 80-μg abaloparatide groups and the teriparatide group were significantly greater than placebo (1.6%). Femoral neck BMD increased by 2.7, 2.2, and 3.1% in abaloparatide, 20-, 40-, and 80-μg groups, respectively, and 1.1% in the teriparatide group. The increase in femoral neck BMD with abaloparatide, 80 μg was significantly greater than placebo (0.8%). Total hip BMD increased by 1.4, 2.0, and 2.6% in the abaloparatide, 20-, 40-, and 80-μg groups, respectively. The total hip increases in the 40- and 80-μg abaloparatide groups were greater than both placebo (0.4%) and teriparatide (0.5%). CONCLUSIONS: Compared with placebo, 24 weeks of daily sc abaloparatide increases BMD of the lumbar spine, femoral neck, and total hip in a dose-dependent fashion. Moreover, the abaloparatide-induced BMD increases at the total hip are greater than with the marketed dose of teriparatide. These results support the further investigation of abaloparatide as an anabolic therapy in postmenopausal osteoporosis. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/25393645/Effects_of_abaloparatide_a_human_parathyroid_hormone_related_peptide_analog_on_bone_mineral_density_in_postmenopausal_women_with_osteoporosis_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2014-3718 DB - PRIME DP - Unbound Medicine ER -